Pancreatic Cancer Research

ResearcherKeimyung UniversityActive in the last 2 years

Chul‐Ho Jeong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4709-3497; OpenAlex author ID A5020105558. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. Last author DOI 10.4014/jmb.2412.12032↗
  2. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Last author DOI 10.1007/s12272-021-01359-x↗
  3. Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells. Last author DOI 10.18632/oncotarget.21572↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Won‐Jun Jang · 3 shared papers, 2017–2025 · strength 0.56
  2. Seongjun Park · 2 shared papers, 2021–2025 · strength 0.49
  3. Dong Joon Kim · 1 shared paper, 2025 · strength 0.33
  4. Dong-Hwan Kim · 1 shared paper, 2025 · strength 0.33
  5. Sang Hoon Joo · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.